Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 3 for:    ruby | France
Previous Study | Return to List | Next Study

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (RUBY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02505048
Recruitment Status : Completed
First Posted : July 22, 2015
Last Update Posted : June 8, 2021
Clovis Oncology, Inc.
Fondation ARC
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to assess the efficacy of a PARP inhibitor, rucaparib, in progressing breast cancer patients and who are carrying a BCRAness profile defined by genomic signature or BRCA 1 or 2 somatic mutation, without known BRCA 1 or 2 germline mutation.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: rucaparib Phase 2

Detailed Description:
This is a single arm, open-label, multicentric, phase II trial, with a Simon two-stage design, assessing the efficacy of a PARP inhibitor, rucaparib, in 41 progressing breast cancer patients with at least one line of chemotherapy at the metastatic setting., and who are carrying a BRCAness profile defined by Clovis genomic signature or a BRCA1 or 2 somatic mutation, without known BRCA1 or 2 germline mutation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Actual Study Start Date : March 2016
Actual Primary Completion Date : February 2019
Actual Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Rucaparib

Arm Intervention/treatment
Experimental: rucaparib

Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.

Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously

Drug: rucaparib
600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.

Primary Outcome Measures :
  1. Clinical Benefit Rate [ Time Frame: 3 years ]
    according to RECIST, is either complete response (CR), partial response (PR) or stable disease (SD) lasting for at least 16 weeks

Secondary Outcome Measures :
  1. Number of patients with complete response, partial response or stable disease [ Time Frame: 3 years ]
    complete response , partial response, or stable disease according to RECIST

  2. Progression free survival [ Time Frame: 3 years ]
    Progression free survival will be assessed from the time of the first dose to disease progression or death from any cause, whichever comes first.

  3. Overall Survival [ Time Frame: 3 years ]
    Overall survival will be assessed from the time of the first dose to death from any cause

  4. Number of patients experiencing an adverse event. [ Time Frame: toxicities will be assessed during the whole treatment period (6 months expected in average) followed by a 2-year post-treatment follow-up period ]
    Adverse events are graded according to the CTCAE V4.03

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women with histologically proven breast cancer.
  2. No Her2 over-expression.
  3. Progressive metastatic disease previously treated with at least one line of chemotherapy at the metastatic setting.
  4. Molecular analysis using the Affymetrix (CytoScan HD, SNP 6.0, or OncoScan) array available from the SAFIR02 protocol, or from other programs.
  5. BRCAness profile as defined by the Clovis genomic signature or BRCA1/2 somatic mutation (without known germline BRCA).
  6. Age ≥ 18 years
  7. WHO Performance Status 0/1
  8. Presence of measurable target lesion according to RECIST criteria v1.1
  9. Patients will have had at least a 21-day wash-out period from last chemotherapy or targeted therapy administration prior to inclusion and should have recover (grade ≤1) from all residual toxicities, excluding alopecia.
  10. Potentially reproductive patients must agree to use an effective contraceptive non-hormonal method or practice adequate methods of birth control or practice complete abstinence while on treatment, and for at least 6 months after the last dose of study drug.
  11. Women of childbearing potential must have a negative serum pregnancy test done within 14 days of enrollment and/or urine pregnancy test 72 hours prior to the administration of the study drug.
  12. Women who are breastfeeding should discontinue nursing prior to the first dose of study drug and until 6 months after the last dose.
  13. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
  14. Patient with social insurance coverage.

Exclusion Criteria:

  1. BRCA1 or 2 germline known mutation.
  2. Life expectancy <3 months.
  3. Less than 14 days from radiotherapy (whatever the indication). Fields should not have involved all target lesions.
  4. Patients previously treated with a PARP inhibitor.
  5. Spinal cord compression and/or symptomatic or progressive brain metastases (unless asymptomatic or treated and stable off steroids for at least 30 days prior to start of study drug).
  6. Patients with all target lesions in a previously irradiated region, except if clear progression has been observed prior to study in at least one of them
  7. Inability to swallow
  8. Major problem with intestinal absorption
  9. Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
  10. Evidence of severe or uncontrolled systemic disease (active bleeding diatheses, or active Hepatitis B, C and HIV)
  11. Previous history of myelodysplastic syndrome
  12. History of hypersensitivity to active or inactive excipients of the rucaparib.
  13. Toxicities of grade ≥2 from any previous anti-cancer therapy, with the exception of alopecia.
  14. Altered haematopoietic or organ function, as indicated by the following criteria:

    • Polynuclear neutrophils <1.5 x 10⁹/L
    • Platelets <100 x 10⁹/L
    • Haemoglobin <90 g/L
    • ALAT/ASAT >2.5 x upper limit of normal (ULN) in the absence of or >5 x ULN in the presence of liver metastases
    • Bilirubin >1.5 x ULN
    • Creatinine clearance ≤30 mL/min (measured or calculated by Cockcroft and Gault formula
  15. Women who are pregnant.
  16. Patients using drugs that are known potent inhibitors or potent inducers of CYP1A2 or CYP3A4 are not eligible if those treatments cannot be substituted before inclusion
  17. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.
  18. Individuals deprived of liberty or placed under the authority of a tutor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02505048

Layout table for location information
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Sponsors and Collaborators
Clovis Oncology, Inc.
Fondation ARC
Layout table for investigator information
Principal Investigator: Fabrice André, MD PhD Gustave Roussy Villejuif
Principal Investigator: Anne Patsouris, MD Institut de Cancerologie de l'Ouest Paul Papin
Layout table for additonal information
Responsible Party: UNICANCER Identifier: NCT02505048    
Other Study ID Numbers: UC-0105/1501
First Posted: July 22, 2015    Key Record Dates
Last Update Posted: June 8, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: In the medical clinical patient file
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents